DAPK1 and neurodegenerative disease: Though the pharmacological application of pyruvate is limited by its stability in solution [55], high working concentration and administration time, pyruvate has a potential to become a lead compound for regulating the new target DAPK1 complex to treat neurodegenerative disease which are caused by glutamate excitotoxicity.